IGM-2644 – Talk Bio

Actionable Insights Powered by AI

IGM Biosciences Halts Autoimmune Projects Amid Layoffs Following Disappointing Trial Data

IGM Biosciences, layoffs, autoimmune diseases, bispecific antibody T cell engagers, imvotamab, IGM-2644, biotech industry